<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01109693</url>
  </required_header>
  <id_info>
    <org_study_id>sun-d</org_study_id>
    <nct_id>NCT01109693</nct_id>
  </id_info>
  <brief_title>Strategic Use of New Generation Antidepressants for Depression</brief_title>
  <acronym>SUN(^_^)D</acronym>
  <official_title>Strategic Use of New Generation Antidepressants for Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center of Neurology and Psychiatry, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyoto University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to establish the optimum treatment strategy for first-line and
      second-line antidepressants in the acute phase treatment of major depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observer-rated depression severity (PHQ-9)</measure>
    <time_frame>9 weeks</time_frame>
    <description>Personal Health Questionnaire-9 is a 9-item structured interview to measure depression severity. It will be rated by blinded telephone interview.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-rated depression severity (BDI-II)</measure>
    <time_frame>9 weeks</time_frame>
    <description>Beck Depression Inventory-II is a 21-item self-report of depression severity. It will be filled in by the patients themselves.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global rating of side effects (FIBSER)</measure>
    <time_frame>9 weeks</time_frame>
    <description>FIBSER stands for Frequency, Intensity and Burden of Side Effects Rating, which is an observer-rated global rating of side effects.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2011</enrollment>
  <condition>Unipolar Major Depressive Episode</condition>
  <arm_group>
    <arm_group_label>Continue sertraline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continue sertraline at the dosage at 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augment with mirtazapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Add mirtazapine to sertraline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to mirtazapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stop sertraline and switch to mirtazapine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline 50 mg/d or 100 mg/d for 6 more weeks</description>
    <arm_group_label>Continue sertraline</arm_group_label>
    <arm_group_label>Augment with mirtazapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirtazapine</intervention_name>
    <description>Augment with or switch to mirtazapine 15-45 mg/d</description>
    <arm_group_label>Augment with mirtazapine</arm_group_label>
    <arm_group_label>Switch to mirtazapine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non-psychotic unipolar major depressive episode (Diagnostic and Statistical Manual,
             Fourth Edition [DSM-IV]) in the preceding month

          -  age 25-75

          -  starting treatment with sertraline clinically indicated

          -  tolerability to sertraline 25 mg/d ascertained

          -  can understand and sign informed consent form

          -  can be contacted by telephone for symptom severity and adverse events

        Exclusion Criteria:

          -  have received antidepressants, mood stabilizers, antipsychotics, psychostimulants,
             electroconvulsive therapy (ECT) or depression-specific psychotherapies in the
             preceding month

          -  history of schizophrenia, schizoaffective disorder or bipolar disorder

          -  current dementia, borderline personality disorder, eating disorder or substance
             dependence

          -  physical disease interfering with sertraline or mirtazapine treatment

          -  allergy to sertraline or mirtazapine

          -  terminal physical illness

          -  currently pregnant or breast-feeding

          -  high risk of imminent suicide

          -  requiring compulsory admission

          -  expected to change doctors within 6 months

          -  cohabiting relatives of research staff

          -  cannot understand Japanese
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiaki A Furukawa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyoto University Graduate School of Medicine / School of Public Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatsuo Akechi, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Nagoya City University Graduate School of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norio Watanabe, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Center of Neurology and Psychiatry, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shinji Shimodera, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kochi University Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitsuhiko Yamada, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Center of Neurology and Psychiatry, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masatoshi Inagaki, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Okayama University Graudate School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naohiro Yonemoto, MSc</last_name>
    <role>Study Director</role>
    <affiliation>National Center of Neurology and Psychiatry, Japan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kazuhira Miki, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Miki Mental Clinic, Yokohama, Japan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nagoya City University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kochi Medical School Hospital</name>
      <address>
        <city>Nangoku</city>
        <state>Kochi</state>
        <zip>783-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2010</study_first_submitted>
  <study_first_submitted_qc>April 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2010</study_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University</investigator_affiliation>
    <investigator_full_name>Toshiaki A. Furukawa</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

